In malignant rhabdoid tumors (MRTs), aberrant co-expression of ACTL6A and ACTL6B is observed, accompanied by altered DNA methylation at differentiation-associated genes and at the neuronal marker NeuN. This evidence concerns the gene RBFOX3 and rhabdoid tumor.